PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by
BRAFV600E mutation
PD-L1
cell growth
papillary thyroid cancer
recurrence-free survival
vemurafenib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
28
12
2020
revised:
27
01
2021
accepted:
27
01
2021
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
PD-L1 inhibition is a promising therapeutic target whose efficacy has been demonstrated in several cancers. Immunohistochemistry was performed to assess PD-L1 protein expression in PTC. We further conducted in vitro analysis to investigate the role of PD-L1 in regulating
Identifiants
pubmed: 33535609
pii: cancers13030555
doi: 10.3390/cancers13030555
pmc: PMC7867170
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32219303
Expert Rev Anticancer Ther. 2016;16(1):13-20
pubmed: 26588948
Int J Cancer. 2016 Sep 1;139(5):1091-7
pubmed: 27082205
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Clin Oncol. 2019 Nov 10;37(32):2987-2999
pubmed: 31403867
PLoS One. 2016 Sep 09;11(9):e0162925
pubmed: 27610620
PLoS One. 2016 Nov 15;11(11):e0166626
pubmed: 27846317
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Int Immunopharmacol. 2017 Nov;52:7-14
pubmed: 28846888
Oncotarget. 2015 Oct 20;6(32):33972-81
pubmed: 26378017
Thyroid. 2017 Apr;27(4):537-545
pubmed: 27825291
Oncogene. 2019 Oct;38(41):6752-6766
pubmed: 31406255
Cancer Res. 2016 Dec 1;76(23):6964-6974
pubmed: 27671674
Int J Cancer. 2018 May 15;142(10):2028-2039
pubmed: 29266240
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Oncol Lett. 2018 Mar;15(3):3321-3328
pubmed: 29435074
Clin Cancer Res. 2011 Dec 1;17(23):7248-64
pubmed: 21868764
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1708-18
pubmed: 16985034
J Pathol. 2007 Oct;213(2):190-9
pubmed: 17703498
Oncotarget. 2016 May 31;7(22):32318-28
pubmed: 27086918
J Endocrinol. 2017 Nov;235(2):R43-R61
pubmed: 28838947
Front Endocrinol (Lausanne). 2017 Nov 20;8:312
pubmed: 29209273
Eur Thyroid J. 2019 Oct;8(5):227-245
pubmed: 31768334
BMC Cancer. 2019 Mar 4;19(1):196
pubmed: 30832606
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Blood. 2008 Apr 1;111(7):3635-43
pubmed: 18223165
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
J Exp Clin Cancer Res. 2019 Jun 13;38(1):253
pubmed: 31196138
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Endocr Relat Cancer. 2017 Feb;24(2):97-106
pubmed: 28093480
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Mol Cancer. 2016 Aug 24;15(1):55
pubmed: 27552968
Oncol Lett. 2020 Jan;19(1):631-640
pubmed: 31897179
JAMA. 2013 Apr 10;309(14):1493-501
pubmed: 23571588
Int J Mol Sci. 2015 Mar 17;16(3):6153-82
pubmed: 25789503
J Clin Oncol. 2015 Jan 1;33(1):42-50
pubmed: 25332244
J Pathol. 2019 Sep;249(1):52-64
pubmed: 30972766
Int J Mol Sci. 2019 Feb 14;20(4):
pubmed: 30769852
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
pubmed: 18000091
CA Cancer J Clin. 2013 Nov-Dec;63(6):374-94
pubmed: 23797834
J Thorac Oncol. 2018 Aug;13(8):1128-1137
pubmed: 29723688
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
Respir Med Case Rep. 2020 May 01;30:101071
pubmed: 32420017
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Surgery. 2018 Jan;163(1):130-136
pubmed: 29128181
Cancer Lett. 2019 Feb 1;442:279-286
pubmed: 30419350
Thyroid. 2014 Sep;24(9):1385-93
pubmed: 24955518
Breast Cancer Res. 2010;12(4):R48
pubmed: 20626886